Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 4/20 | 0.37 |
| ▸ | MAOA | P21397 | 3/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13495125 | 0.74 | L3MBTL1 (0.47) | KCNH2ESR1ESR2BACE1DAO | |
| SCHEMBL64650 | 0.74 | BACE1 (0.49) | KCNH2SMN1; SMN2ESR1ESR2BACE1 | |
| SCHEMBL27768180 | 0.72 | RAB9A (0.52) | HSD17B10KCNH2SMN1; SMN2ESR1ESR2 | |
| SCHEMBL23929224 | 0.71 | KCNH2 (0.44) | KCNH2ESR1ESR2BACE1DAO | |
| Hydrochloric Acid SCHEMBL23120669 | 0.71 | LOXL2 (0.39) | TP53ALOX15MAPK1HSD17B10SMN1; SMN2 | |
| SCHEMBL24622014 | 0.70 | KCNH2 (0.43) | TP53KCNH2ESR1ESR2BACE1 | |
| SCHEMBL23929223 | 0.70 | KCNH2 (0.43) | KCNH2ESR1ESR2BACE1DAO | |
| SCHEMBL14719095 | 0.69 | DAO (0.55) | KCNH2BACE1DAO | |
| SCHEMBL23957471 | 0.69 | HCAR2 (0.45) | KCNH2ESR1ESR2BACE1DAO | |
| SCHEMBL239535 | 0.68 | MAPK1 (0.62) | TP53ALOX15MAPK1HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140181-A1 | COMBINATION THERAPY OF RADIATION AND A COX-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000038716-A1 | COMBINATION THERAPY OF RADIATION AND A COX-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | disclosed |
| US-20050026919-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026919-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system | ACHE, PTGER2, PTGS2 | TP53 4276/4885ALOX15 228/4885MAPK1 2267/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | TP53 2487/4885ALOX15 50/4885MAPK1 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.